The company, which was born out of the merger in July 2015 of Targovax and Oncos Therapeutics, presented encouraging Phase I/II results in February 2017 on its prospective targeted immunotherapeutic TG01, in resected pancreatic cancer.

Those results led the company's share price to jump by a third in a day's trading.